EAST RUTHERFORD, NJ, September 19, 2024 /CNW/ — Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new technology for liquid-phase peptide synthesis (LPPS) using a traditional active pharmaceutical ingredient. API) batch and continuous flow reactors, eliminating reliance on specialized, solid-state reactors. This new LPPS technology reduces the need for solvent and the need for excess reagents compared to conventional peptide synthesis methods.
“In the past few years, we have made significant investments in the research and development of complex synthetics, specifically to reduce the economic and environmental effects of the production of peptides and oligonucleotides,” said Dr. Matt BioChief Scientific Officer, Cambrex. “Our new LPPS technology offers a cost-effective and environmentally sustainable solution compared to traditional peptide synthesis, significantly reducing solvent consumption and allowing for the replacement of sustainable solvents.”
LPPS technology supports peptides up to 12 residues in length, while larger peptides are assembled in a liquid, using a particle assembly method. Processes made with Cambrex’s LPPS technology can be reduced in the same way as traditional small molecules.
In addition to LPPS, Cambrex has also developed unique capabilities for peptide and protein crystallization, including a crystallization analysis platform specifically for the discovery of crystalline forms of peptides and proteins. Crystallization can provide improved product quality and stability and reduce the need for time-consuming chromatography and lyophilization.
“With the clinical and commercial success of peptide-based therapies, it is imperative that we provide industry-leading solutions to develop and quantify peptide candidates,” he said. Thomas LoewaldCEO at Cambrex.
Cambrex will continue to invest in R&D across complex synthetic processes, including the development of additional technologies for peptides, as well as new research into the use of artificial intelligence to improve oligonucleotide applications.
About Snapdragon Chemistry
Snapdragon Chemistry, a Cambrex company, specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, using the latest automated technology and equipment of assets to solve complex operational problems and progress analysis. It has R&D and production at its headquarters Waltham, MassachusettsSnapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) providing drug development and manufacturing across the entire drug life cycle, as well as comprehensive testing services and IND services.
With over 40 years of experience and a team of 2,000 professionals serving global clients from North America and EuropeCambrex offers a wide range of specialty drug technologies and capabilities, including continuous flow, controlled substances, solid state science, material characterization, and high potency APIs.
Logo: https://mma.prnewswire.com/media/2236065/4360596/Cambrex_logo.jpg
Logo: https://mma.prnewswire.com/media/2076582/4360601/Snapdragon_Logo.jpg
See original story: https://www.prnewswire.com/news-releases/cambrex-announces-new-liquid-phase-peptide-synthesis-manufacturing-technology-302251981.html
SOURCE Cambrex
See original news: http://www.newswire.ca/en/releases/archive/September2024/19/c8516.html
#Cambrex #Announces #LiquidPhase #Peptide #Synthesis #Manufacturing #Technology